Advances in Disease Theranostics (Technical Insights)


USD 4,950.00

* Required Fields

USD 4,950.00


Be the first to review this product

This research service analyses the latest developments that has occurred in the field of theranostics, both from a technology and industry perspective.

Table of Contents

Advances in Disease Theranostics (Technical Insights), Executive SummaryResearch Scope and MethodologyResearch ScopeResearch MethodologyIndustry Overview; Trends; and Key FindingsIndustry Overview and TrendsNoteworthy DevelopmentsAdvances in Disease Theranostics (Technical Insights), Technology Adoption Factor AnalysisTechnology PrimerTheranostics--A Whole New ConceptWhat’s in Theranostics?--Assessing the Applications and ImplicationsSome Exemplars of Theranostic ApproachesForce Field AnalysisThe Driving ForcesThe Restraining Forces and ChallengesStrategic Evaluation of the Competitive Environment (Analyst's Perspectives)Strategic Evaluation of the Theranostics Sector--SWOT AnalysisStrategic Assessment of Competitive Landscape and Technology Attractiveness of TheranosticsStrategic Analysis of the Market Opportunities; Options; and Trends Theranostics Market Opportunity Analysis--A Concept Whose Influence Cannot be StifledAnalysis of Options for Maximal Capitalization on Theranostics--Pharma versus Diagnostic CompaniesAnalysis of Current Trends and Future Outlook for TheranosticsAdvances in Disease Theranostics (Technical Insights), Case Studies of Global Innovations in the Theranostics Sector Corporate Innovations--WorldPredictive Tests Predict Right Therapy for the Right Patient--DenmarkA ‘Food Drug’ a Day Could Keep Heart Diseases Away–Revolutionizing Cardio-Theranostics--UKAnalyzing Genes by Noninvasive Skin Sampling Inspires Novel Theranostic Applications--USAFrom Novel Targets to Ideal Theranostics--USAProtein Arrays Paint an Individual’s ‘Cell Signaling Portrait’–Taking Theranostics to the Proteome Level--USASimple Chemical Treatment Paves the Way for Neuronal Theranostics--USAFrom a Generic to a Genetic Approach—Customizing Cancer Treatments--USAHarnessing Protein Power to Advance Theranostics in Untapped Disease Sectors--USAGuiding CML Therapy with Standardized Companion Diagnostics--USAAcademic Innovations--WorldFrom Hydrogels to Theranostics–A Whole New Approach to Multiplexed Diagnosis--USA'Rapid' Tracking of Biomarkers in AML Therapy-- USAAdvances in Disease Theranostics (Technical Insights), Patents Analysis and Key contactsKey Patents in the Theranostics Domain (2005 to 2008)Key Corporate Patents--American Patents (USPTO)Key Corporate Patents--World Patents (WIPO)Key Academic PatentsGeographical Analysis of Patent Distribution–World Theranostics SectorKey ContactsKey Industry ContactsKey Academic ContactsAdvances in Disease Theranostics (Technical Insights), Decision Support DatabasesDatabase TablesTotal Healthcare Expenditure--World (2002 to 2012)Pharmaceutical R&D Expenditure--World (2002 to 2012)Number of Physicians--World (2002 to 2012)Number of Hospitals--World (2002 to 2012)Incidence of Breast Cancer--World (2002 to 2012)

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.